Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
success tags : Fda save search
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
Published: 2024-03-14 (Crawled : 21:00) - globenewswire.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 3.05%
H: 14.23%
C: 12.57%
fda update meeting therapeutics study
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
Published: 2024-02-21 (Crawled : 15:30) - biospace.com/
ENSC | $0.5583 1.58% 43K
|
Health Technology
|
| O: 1.07%
H: 2.5%
C: -3.12%
pf614 fda opioid meeting
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
Published: 2024-02-20 (Crawled : 12:30) - globenewswire.com
MTNB | $0.1818 0.17% 0.0% 520K
|
Health Technology
|
| O: 4.35%
H: 11.21%
C: -0.46%
mat2203 fda treatment biopharma trial agreement
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
Published: 2024-02-16 (Crawled : 12:30) - globenewswire.com
IXHL | $2.28 -1.29% 32K
|
Manufacturing
|
| O: -6.59%
H: 15.33%
C: 13.14%
fda solution meeting
New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval
Published: 2024-02-01 (Crawled : 21:00) - biospace.com/
TNXP | $0.1587 1.21% 1.2% 950K
|
Health Technology
|
| O: 2.78%
H: 6.05%
C: 4.59%
fda fibromyalgia approval hope trial results
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Published: 2024-01-05 (Crawled : 14:30) - biospace.com/
COYA | News | $8.28 3.24% 3.14% 120K
|
|
| O: 1.94%
H: 2.79%
C: 0.0%
fda sclerosis treatment therapeutics
Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
Published: 2023-12-13 (Crawled : 14:30) - globenewswire.com
PCSA | $1.67 4.38% 4.19% 40K
|
Producer Manufacturing
|
| O: -1.36%
H: 0.0%
C: -24.38%
fda pharmaceuticals meeting
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
Published: 2023-12-06 (Crawled : 13:00) - globenewswire.com
DERM | $3.425 -3.25% -3.36% 60K
|
|
| O: -1.92%
H: 10.12%
C: 8.17%
FBIO | $1.785 -1.38% -1.4% 120K
|
Health Technology
|
| O: 0.75%
H: 7.43%
C: 4.09%
dfd-29 fda corporation treat meeting medical
Scilex Holding Company announces successful FDA audit of enhanced ZTlido® manufacturing facility in Japan
Published: 2023-11-30 (Crawled : 08:00) - globenewswire.com
SCLX | $0.8407 -13.92% -16.18% 1.7M
|
|
| O: -2.14%
H: 2.19%
C: -8.76%
ztlido fda company japan
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT
Published: 2023-11-14 (Crawled : 13:30) - prnewswire.com
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 6.19%
H: 3.33%
C: -6.67%
fda cancer meeting therapeutics
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
OCUP | News | $1.52 -1.3% -1.32% 90K
|
Health Technology
|
| O: 5.23%
H: 2.65%
C: -8.94%
apx3330 fda pharma meeting diabetic phase 2
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder
Published: 2023-10-16 (Crawled : 12:00) - globenewswire.com
BNOX | $0.9232 -4.33% 25K
|
n/a
|
| O: 5.15%
H: 11.52%
C: 8.58%
bnc210 fda meeting program
Coherus Can't Catch a Regulatory Break; Appili Sees FDA Success
Published: 2023-09-26 (Crawled : 14:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
PRGO | $31.23 2.43% 0.0% 960K
|
Health Technology
|
| O: -0.65%
H: 0.5%
C: -1.59%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
fda success
Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023
Published: 2023-09-06 (Crawled : 11:00) - globenewswire.com
APLT | $4.285 -3.92% -4.08% 770K
|
Health Technology
|
| O: 15.08%
H: 39.31%
C: 24.14%
at-007 fda treatment meeting therapeutics
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Published: 2023-07-05 (Crawled : 12:00) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.19%
H: 1.07%
C: 0.65%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: 1.24%
H: 0.0%
C: -7.09%
al102 fda tumors treatment pharmaceuticals meeting phase 2
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025
Published: 2023-05-08 (Crawled : 12:00) - biospace.com/
ACST | $2.9 0.69% 0.69% 8.4K
|
Health Technology
|
| O: 0.49%
H: 3.33%
C: 2.22%
gtx-104 fda study
SINTX ANNOUNCES SUCCESSFUL FDA 510(k) PRE-SUBMISSION MEETING FOR SILICON NITRIDE-PEEK COMPOSITE SPINE IMPLANTS
Published: 2022-09-08 (Crawled : 14:20) - globenewswire.com
SINT | $0.0385 7.54% 7.01% 45M
|
Health Technology
|
| O: -0.77%
H: 10.0%
C: 2.5%
fda spine meeting
IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma
Published: 2023-04-23 (Crawled : 16:20) - prnewswire.com
IDYA | News | $39.85 2.13% 2.08% 1.3M
|
Health Technology
| Email alert
Add to watchlist
fda melanoma approval positive meeting trial
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
Published: 2023-04-05 (Crawled : 16:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M
|
Health Technology
|
| O: 0.75%
H: 1.48%
C: -2.22%
nm-136 fda obesity biopharma meeting
Athersys Announces Successful Type B Meeting with the FDA
Published: 2023-03-22 (Crawled : 13:00) - biospace.com/
ATHX | $0.1018 -40.86% 95M
|
Health Technology
|
| O: 5.93%
H: 20.8%
C: 14.4%
fda meeting type-b meeting
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.